JP2018521643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521643A5 JP2018521643A5 JP2017564550A JP2017564550A JP2018521643A5 JP 2018521643 A5 JP2018521643 A5 JP 2018521643A5 JP 2017564550 A JP2017564550 A JP 2017564550A JP 2017564550 A JP2017564550 A JP 2017564550A JP 2018521643 A5 JP2018521643 A5 JP 2018521643A5
- Authority
- JP
- Japan
- Prior art keywords
- viral
- delivery system
- replication
- virus
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003612 virological effect Effects 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 230000010076 replication Effects 0.000 claims description 36
- 239000002924 silencing RNA Substances 0.000 claims description 32
- 239000003999 initiator Substances 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 21
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 16
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 230000030279 gene silencing Effects 0.000 claims description 16
- 238000012226 gene silencing method Methods 0.000 claims description 16
- 108091070501 miRNA Proteins 0.000 claims description 16
- 239000002679 microRNA Substances 0.000 claims description 16
- 239000004055 small Interfering RNA Substances 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 11
- 108010061833 Integrases Proteins 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 6
- 208000016361 genetic disease Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 206010023927 Lassa fever Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 241000701822 Bovine papillomavirus Species 0.000 claims description 2
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 206010001584 alcohol abuse Diseases 0.000 claims description 2
- 208000025746 alcohol use disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229940053128 nerve growth factor Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 108010046910 brain-derived growth factor Proteins 0.000 claims 1
- 231100000878 neurological injury Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173784P | 2015-06-10 | 2015-06-10 | |
| US62/173,784 | 2015-06-10 | ||
| PCT/US2016/036519 WO2016200997A1 (en) | 2015-06-10 | 2016-06-08 | Non-integrating viral delivery system and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021627A Division JP2021072865A (ja) | 2015-06-10 | 2021-02-15 | 非組み込みウイルス送達システムおよびその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521643A JP2018521643A (ja) | 2018-08-09 |
| JP2018521643A5 true JP2018521643A5 (enExample) | 2019-07-11 |
| JP6924487B2 JP6924487B2 (ja) | 2021-08-25 |
Family
ID=57503988
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564550A Active JP6924487B2 (ja) | 2015-06-10 | 2016-06-08 | 非組み込みウイルス送達システムおよびその使用の方法 |
| JP2021021627A Pending JP2021072865A (ja) | 2015-06-10 | 2021-02-15 | 非組み込みウイルス送達システムおよびその使用の方法 |
| JP2023099918A Withdrawn JP2023113963A (ja) | 2015-06-10 | 2023-06-19 | 非組み込みウイルス送達システムおよびその使用の方法 |
| JP2025063242A Pending JP2025114562A (ja) | 2015-06-10 | 2025-04-07 | 非組み込みウイルス送達システムおよびその使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021627A Pending JP2021072865A (ja) | 2015-06-10 | 2021-02-15 | 非組み込みウイルス送達システムおよびその使用の方法 |
| JP2023099918A Withdrawn JP2023113963A (ja) | 2015-06-10 | 2023-06-19 | 非組み込みウイルス送達システムおよびその使用の方法 |
| JP2025063242A Pending JP2025114562A (ja) | 2015-06-10 | 2025-04-07 | 非組み込みウイルス送達システムおよびその使用の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180161455A1 (enExample) |
| EP (1) | EP3307894B1 (enExample) |
| JP (4) | JP6924487B2 (enExample) |
| WO (1) | WO2016200997A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| WO2017213697A1 (en) * | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| WO2025255019A1 (en) * | 2024-06-03 | 2025-12-11 | Mayo Foundation For Medical Education And Research | Transcription and replication particles and their use as antiviral therapies |
| US12480129B1 (en) * | 2024-09-17 | 2025-11-25 | Wyvern Pharmaceuticals Inc. | Composition for regulating production of interfering ribonucleic acid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6014094A (en) * | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| CA2300957A1 (en) * | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| AU1124499A (en) * | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| ATE286138T1 (de) * | 1998-03-20 | 2005-01-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren |
| WO2004053137A2 (en) * | 2002-12-11 | 2004-06-24 | Cytos Biotechnology Ag | Method for protein production |
| EP1644508A1 (en) * | 2003-07-11 | 2006-04-12 | Cytos Biotechnology AG | Gene expression system |
| CA2585523A1 (en) * | 2004-11-02 | 2006-05-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof |
| WO2007133674A2 (en) * | 2006-05-12 | 2007-11-22 | Lentigen Corporation | Lentiviral vector compositions, methods and applications |
| EP2342321B1 (en) * | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| JP2012508591A (ja) * | 2008-11-14 | 2012-04-12 | ライフ テクノロジーズ コーポレーション | 細胞を操作するための組成物および方法 |
| WO2011119942A1 (en) * | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
| EP2878674A1 (en) * | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
-
2016
- 2016-06-08 WO PCT/US2016/036519 patent/WO2016200997A1/en not_active Ceased
- 2016-06-08 JP JP2017564550A patent/JP6924487B2/ja active Active
- 2016-06-08 EP EP16808223.8A patent/EP3307894B1/en active Active
- 2016-06-08 US US15/580,661 patent/US20180161455A1/en active Pending
-
2021
- 2021-02-15 JP JP2021021627A patent/JP2021072865A/ja active Pending
-
2023
- 2023-06-19 JP JP2023099918A patent/JP2023113963A/ja not_active Withdrawn
-
2025
- 2025-04-07 JP JP2025063242A patent/JP2025114562A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lindsley et al. | Eosinophil responses during COVID-19 infections and coronavirus vaccination | |
| Li et al. | Inhibition of double‐strand DNA‐sensing cGAS ameliorates brain injury after ischemic stroke | |
| Alexopoulou et al. | New approaches to the treatment of chronic hepatitis B | |
| Tian et al. | A peptide-based nanofibrous hydrogel as a promising DNA nanovector for optimizing the efficacy of HIV vaccine | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| Shwetank et al. | PD-1 dynamically regulates inflammation and development of brain-resident memory CD8 T cells during persistent viral encephalitis | |
| Moser et al. | Increased vaccine tolerability and protection via NF-κB modulation | |
| Espín-Palazón et al. | TNFα impairs rhabdoviral clearance by inhibiting the host autophagic antiviral response | |
| JP6924487B2 (ja) | 非組み込みウイルス送達システムおよびその使用の方法 | |
| JP2018523668A5 (enExample) | ||
| Gooshe et al. | The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes | |
| JP2019520814A5 (enExample) | ||
| JP2019527055A5 (enExample) | ||
| PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| JP2024073653A (ja) | 遺伝子改変リンパ球の製造方法 | |
| RU2018101139A (ru) | Фармацевтические препараты для лечения вирусных инфекций глаза | |
| JP2000500124A (ja) | ウイルス、腫瘍、細菌および寄生体の抑制において免疫応答を特に調節するための医薬 | |
| Castillo et al. | Myeloid cell reservoirs: role in HIV-host interplay and strategies for myeloid reservoir elimination | |
| US20240024459A1 (en) | Method for producing an antigen corresponding to the inactivated sars-cov-2 virus, antigen corresponding to the inactivated sars-cov-2 virus, antigenic composition, kits, and uses thereof | |
| Huo et al. | Molecular cloning of chicken IL-7 and characterization of its antiviral activity against IBDV in vivo | |
| ATE486088T1 (de) | Hiv-impfstoff | |
| Gaajetaan et al. | The type I interferon response during viral infections: a “SWOT” analysis | |
| US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
| Zare-Zardini et al. | Antimicrobial peptides as potent compounds for reduction of COVID-19 infection | |
| NO322176B1 (no) | Anvendelse av pox inducere omfattende en kombinasjon av henholdsvis flere pox virus og parapox virus for fremstilling av medikamentet for prefinal tumorterapi for a lindre smerte og optimalisere velbefinnende til pasienter. |